Dendreon Corporation's Provenge Vaccine, A Hedge Fund Manager And The SEC

Published: Dec 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a curious postscript to the long-running saga that has been the Provenge vaccine, the US Securities and Exchange Commission has levied a $25,000 fine on a former hedge fund analyst, who caused a stir by writing a medical study that questioned the benefit of the medicine and, subsequently, claimed she received threatening remarks on investor message boards.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news